Javed Malik, DO
Hematology & Oncology · South Bend, INNPI 1457666497
Payments from drug & device makers
Across 130 payments — averaging $27.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Genentech USA, Inc.$220
- AstraZeneca$161
- E.r. Squibb & Sons, L.L.C.$158
- Amgen$131
- Johnson & Johnson$122
- plus $1K from 36 others
What the payments were for
- Food & beverage$2,20761%
- Education$1294%
- Other$1,28035%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 28 | $1,533 |
| Genentech USA, Inc. | 10 | $220 |
| AstraZeneca | 9 | $161 |
| E.r. Squibb & Sons, L.L.C. | 8 | $158 |
| Amgen | 5 | $131 |
| Johnson & Johnson(2 entities) | 6 | $122 |
| Abiomed | 1 | $119 |
| Merck | 6 | $105 |
| Bristol Myers Squibb | 5 | $102 |
| Daiichi Sankyo Inc. | 3 | $67 |
| Incyte Corporation | 4 | $66 |
| Pfizer | 4 | $64 |
| Sanofi | 4 | $62 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $56 |
| EMD Serono, Inc. | 2 | $44 |
| Geron Corporation | 1 | $42 |
| Stryker | 1 | $41 |
| Eisai Inc. | 2 | $37 |
| Pharmacosmos Therapeutics Inc. | 2 | $36 |
| AVEO Pharmaceuticals, Inc. | 2 | $32 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Seagen Inc. | 2 | $30 |
| Adaptive Biotechnologies Corporation | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Genmab U.S., Inc. | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Sobi, Inc | 1 | $19 |
| AbbVie | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $18 |
| GSK | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Mirati Therapeutics, Inc. | 1 | $17 |
| Clovis Oncology, Inc. | 2 | $15 |
| Array Biopharma Inc | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,616 in reported general payments places this provider in the 35th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 42 | $566,380 |
| ImbruvicaIbrutinib | 29 | $486,461 |
| RevlimidLenalidomide | 24 | $440,505 |
| CalquenceAcalabrutinib Maleate | 22 | $353,808 |
| VenclextaVenetoclax | 22 | $272,856 |
| Abiraterone Acetate | 182 | $262,461 |
| XtandiEnzalutamide | 17 | $235,793 |
| IbrancePalbociclib | 14 | $227,585 |
| EliquisApixaban | 28 | $20,321 |
| Exemestane | 25 | $3,377 |
| Imatinib Mesylate | 11 | $2,316 |
| Letrozole | 95 | $1,860 |
| Dexamethasone | 76 | $1,333 |
| Prednisone | 102 | $537 |
| Anastrozole | 38 | $487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $56 | $486,46129 claims |
| Bristol Myers SquibbRevlimid | $102 | $440,50524 claims |
| AstraZenecaCalquence | $161 | $353,80822 claims |
| AbbVieVenclexta | $18 | $272,85622 claims |
| PfizerIbrance, Eliquis | $64 | $247,90642 claims |
| Astellas Pharma US IncXtandi | $13 | $235,79317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in South Bend
- Gregory DurmIndianapolis$22.7M
- Nabil AdraIndianapolis$13.2M
- Attaya SuvannasankhaIndianapolis$8.2M
- Zhentao ZhangFort Wayne$6.4M
- Shadia JalalIndianapolis$4.6M
- Ahad SadiqFort Wayne$4M
- Ruemu BirhirayIndianapolis$4M
- Richard GaynorIndianapolis$3.7M
- Ebenezer KioGoshen$2.8M
- Chandler ParkCorydon$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.